reschedule the pharmaceutical composition of crystalline polymorph psilocybin in a drug product approved by the Food and Drug Administration as a Schedule IV controlled substance.

Summary

The bill changes South Dakota’s controlled‑substance schedule to exempt the pharmaceutical composition of crystalline polymorph psilocybin that the FDA has approved, removing it from the most restrictive Schedule I. By doing so, the product is treated like other Schedule IV drugs, allowing it to be prescribed and dispensed under state law. This aligns state regulation with the federal approval and opens a pathway for medical use.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share